Viatris Pty Ltd

Viatris Pty Ltd is an Australian pharmaceutical company headquartered in Sydney, New South Wales. Established in 2014, it operates as a proprietary company, limited by shares, and is registered for Goods and Services Tax (GST) purposes. The company is a subsidiary of Viatris Inc., a global healthcare corporation formed in 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer. (viatris.com.au) Viatris Pty Ltd plays a significant role in Australia's pharmaceutical distribution network, providing access to a broad range of high-quality, trusted medicines across various therapeutic areas. (viatris.com.au)

Viatris Pty Ltd operates a robust distribution network within Australia, with a state-of-the-art warehouse and distribution centre located in Bundamba, Queensland. This facility, equivalent in size to 43 Olympic pools, stores extensive volumes of stock and a wide range of critical products under one roof. Orders can be made from this warehouse and shipped anywhere around the country overnight, ensuring timely delivery to meet the healthcare needs of Australians. (viatris.com.au) Additionally, Viatris Pty Ltd exports medicines to over 40 countries, leveraging its global manufacturing and distribution capabilities to reach a broader market. (viatris.com.au)

Viatris Pty Ltd serves as a primary wholesaler in Australia's pharmaceutical supply chain. The company imports a diverse portfolio of medicines, including prescription drugs, over-the-counter (OTC) products, and generics, to meet the healthcare needs of the Australian population. By partnering with healthcare professionals, government bodies, and patient groups, Viatris Pty Ltd ensures the availability of affordable, high-quality medicines across the country. (viatris.com.au)

Viatris Pty Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $660,000 USD across 15 shipments. The top five products imported are Fluticasone ($650,000 USD) and Brufen ($10,000 USD), accounting for 98.5% and 1.5% of the total import value, respectively. This concentration indicates a strategic choice to focus on specific products, potentially leveraging favorable pricing or supplier relationships. However, such dependency on a limited number of products and suppliers may pose risks related to supply chain disruptions or changes in market demand. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the period.

Viatris Pty Ltd's supply chain resilience is supported by its partnerships with multiple Indian suppliers, including CIPLA Limited, Micro Labs Limited, Mylan Laboratories Limited, Medreich Limited, Sharon Bio-Medicine Limited, and Intas Pharmaceuticals Limited. This diversified supplier base enhances the company's ability to mitigate risks associated with single-source dependency. The importation of 136 unique formulations further demonstrates the company's commitment to offering a broad range of products to meet diverse patient needs. While the supply chain appears robust, ongoing monitoring of supplier performance and market conditions is essential to maintain resilience.

Viatris Pty Ltd's focused sourcing strategy positions the company to negotiate favorable terms with its Indian suppliers, potentially securing competitive pricing and ensuring a reliable supply of key products. For Indian exporters, this presents an opportunity to strengthen partnerships with Viatris Pty Ltd by offering high-quality products that align with the company's therapeutic focus. Expanding the product range and ensuring consistent supply can enhance the attractiveness of Indian exporters as alternative suppliers to Viatris Pty Ltd.

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority responsible for overseeing the importation, manufacturing, and distribution of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which outlines the regulatory framework for ensuring the safety, efficacy, and quality of medicines available in Australia. For Indian generics to be marketed in Australia, they must undergo the TGA's evaluation process, which includes assessment of the product's quality, safety, and efficacy, as well as compliance with Australian labeling and packaging requirements.

Import licensing in Australia is governed by the TGA, which requires that all imported therapeutic goods be included in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in the country. Manufacturers and suppliers must provide evidence of Good Manufacturing Practice (GMP) compliance, typically through certificates from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that the manufacturing processes meet international standards for quality and safety. Additionally, wholesalers like Viatris Pty Ltd must hold a valid wholesale distribution authorization issued by the TGA to legally distribute therapeutic goods within Australia.

Imported pharmaceutical products must undergo batch testing to confirm their quality, safety, and efficacy before being released into the Australian market. Stability studies are also required to ensure that products maintain their quality throughout their shelf life under Australian storage conditions. Labeling requirements include the use of English language, clear dosage instructions, and compliance with Australian standards for packaging and labeling. Serialization mandates may apply to certain products to enhance traceability and prevent counterfeit medicines from entering the supply chain.

Between 2024 and 2026, the TGA has implemented several policy changes affecting the importation of Indian pharmaceuticals into Australia. These include updates to the ARTG inclusion process, revisions to GMP certification requirements, and enhancements to post-market surveillance measures. These changes aim to strengthen the regulatory framework, ensuring that imported medicines meet the highest standards of quality and safety for Australian patients.

Viatris Pty Ltd's product strategy focuses on therapeutic areas with high demand and significant patient impact, such as respiratory conditions. The company's importation of Fluticasone, a corticosteroid used to treat asthma and allergic rhinitis, aligns with this focus. The substantial import value of Fluticasone indicates a strong market demand and the company's commitment to providing effective treatments for respiratory conditions. The inclusion of Brufen, a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, suggests a strategic approach to offering a comprehensive range of therapeutic options to meet diverse patient needs.

Viatris Pty Ltd's sourcing strategy emphasizes the importation of generic drugs, leveraging cost-effective manufacturing processes to provide affordable medicines to the Australian market. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a preference for ready-to-use products that meet the therapeutic needs of patients. India's established pharmaceutical industry, with its adherence to international GMP standards, positions it as a key supplier for Viatris Pty Ltd's procurement needs.

Based on its product mix, Viatris Pty Ltd serves multiple segments of the Australian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse portfolio enables it to address the needs of various healthcare providers and patients, ensuring broad access to essential medicines across the country.

There is a realistic opportunity for new Indian suppliers to partner with Viatris Pty Ltd, particularly if they can offer high-quality generic products that align with the company's therapeutic focus areas. Gaps in Viatris Pty Ltd's current sourcing may exist in specific therapeutic categories or formulations not currently covered. Indian exporters can explore these opportunities by ensuring compliance with Australian regulatory requirements and demonstrating the quality and efficacy of their products.

Indian exporters seeking to supply Viatris Pty Ltd and the Australian market must obtain GMP certifications from recognized authorities such as the EU, WHO, or PIC/S. They must also ensure that their products are included in the ARTG and comply with Australian labeling and packaging standards. Additionally, maintaining a consistent supply of high-quality products and adhering to agreed-upon delivery schedules are essential to meet the expectations of Viatris Pty Ltd and the Australian market.

Indian exporters should initiate contact with Viatris Pty Ltd by presenting their product portfolio, highlighting compliance with Australian regulatory standards, and demonstrating the quality and efficacy of their products. Participating in relevant tenders and industry events can enhance visibility and facilitate networking opportunities. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and approvals, is crucial. Exporters should also establish clear communication channels and set realistic timelines for product evaluation, approval, and distribution to align with Viatris Pty Ltd's operational requirements.